Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis|
|Citation:||Blood, 2003; 102(1):276-283|
|Publisher:||American Society of Hematology|
|Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, and Tim Hughes|
|Abstract:||Abstract not available|
|Keywords:||Humans; Disease Progression; Piperazines; Pyrimidines; Fusion Proteins, bcr-abl; Adenosine Triphosphate; Prognosis; Survival Analysis; DNA Mutational Analysis; Binding Sites; Protein Structure, Tertiary; Drug Resistance, Neoplasm; Mutation; Genes, abl; Adult; Aged; Middle Aged; Female; Male; Leukemia, Myelogenous, Chronic, BCR-ABL Positive|
|Rights:||© 2003 by The American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.